EUROPEAN REIMBURSEMENT STRATEGY
Local setup of the European strategy via an established network of local partners
Reimbursement environment scan at national levels
Systematic literature review covering clinical, health economics and real-life evidence
Country-specific patient pathway and therapeutic strategy based on national recommendations
Healthcare system and country-specific reimbursement pathways description
Competitive landscape
Coding and reimbursement analysis: DRG-based payment, add-on DRG top up payment, early access scheme, global budget, fee-for-services, ...
DRG tariff estimation based on consistent clinical scenarios and hands-on knowledge of local tariff algorithms
Strategic reimbursement analysis at national levels
Regulatory analysis associated with the reimbursement analysis, if needed
Evidence gap analysis with recommendations for evidence generation to best meet country-specific clinical and HEOR requirements
Identification of unmet / not sufficiently met needs and associated target population for the reimbursement claim
Determination of the level of adoption by the medical community
Determination of optimal country-specific reimbursement pathway with eligibility requirements if any (e.g restriction of indication and/or of user centers, evidence requirements...)
Development of payer value proposition and value story
Identification of country-specific drivers and barriers for adoption and reimbursement : acceptance of treatment & willingness to pay based on commissioning policy and relevant HTA
Drafting of the contact plan : mapping of relevant payers, HTA bodies, KOLs, medical societies, insurance bodies, … specifying the rules of engagement (early meeting, conference call, physical meeting, …)
​
Strategic recommendation at European level
Recommended market access plan taking into account priority countries for market entry, including detailed process description, contact plan, timeline and budget estimation